{
    "clinical_study": {
        "@rank": "132820", 
        "arm_group": {
            "arm_group_label": "Metronomic Capecitabine  and AI", 
            "arm_group_type": "Experimental", 
            "description": "Postmenopausal Hormone receptor positive breast cancer patients who wanted to conserve breast were enrolled to receive capecitabine 500mg/tid p.o plus one of the aromatase inhibitors (AIs):Anastrozole 1mg/day p.o, and who had first line or second line Letrozole therapy failure were switched to capecitabine 500mg/tid p.o plus Exemestane 25mg/day p.o\uff1bor Exemestane therapy failure were switched to capecitabine 500mg/tid p.o plus Letrozole 2.5mg/day p.o."
        }, 
        "brief_summary": {
            "textblock": "The present study is to determine the adverse effects and clinical efficacy of AI combined\n      with Capecitabine metronomic chemotherapy in postmenopausal breast cancer patients with\n      Estrogen receptor and/or Progestrogen receptor positive."
        }, 
        "brief_title": "Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Capecitabine (Xeloda \u00ae) is currently the most biologically active oral fluoropyrimidine\n      drug, and is widely used as first-line and second-line rescue therapy for advanced breast\n      cancer ,third-generation aromatase inhibitors (AI) is the preferred adjuvant endocrine\n      therapy for Postmenopausal hormone-sensitive breast cancer. Study showed that AI combined\n      with metronomic chemotherapy could improve the objective response and clinical benefit in\n      neoadjuvant therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Hormone receptor positive;\n\n          2. previously untreated patients who do not receive hormonal therapy, or initial\n             endocrine treatment failure or first -line endocrine treatment of relapse and\n             metastasis failure;\n\n          3. patients who do not receive hormonal therapy must be histologically confirmed\n             invasive ductal carcinoma, can be surgery, but must be satisfied one of the\n             following: (1) elderly (\u226570 years), or with severe heart or other systemic\n             complications, belonging to high risk of general anesthesia, (2) have will of\n             conserving the breast,but larger tumors (\u22653cm) not suitable for breast-conserving\n             surgery.\n\n          4. patients with metastatic breast cancer must have evaluable lesions\n\n          5. normal laboratory values:\n\n          6. informed consent (ethical approval document No. :1112105-1);\n\n          7. life expectancy of at least 3 months;\n\n          8. Postmenopausal or premenopausal with bilateral oophorectomy.\n\n        Exclusion Criteria:\n\n          1. have had radiotherapy or other local treatment for measurable lesions before the\n             start of study received within 3 months\n\n          2. organ transplant (except for autologous or allogeneic bone marrow transplantation);\n\n          3. have evidences of central nerve system metastases or have a history of mental illness\n             that uncontrol;\n\n          4. unable to swallow tablets, or malabsorption patients, or patients with poor upper\n             gastrointestinal integrity;\n\n          5. unwilling or unable to comply with study protocol or unable to meet the follow up;\n\n          6. patients who researchers considered were not suitable to participate."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01924078", 
            "org_study_id": "Metronomic Therapy"
        }, 
        "intervention": [
            {
                "arm_group_label": "Metronomic Capecitabine  and AI", 
                "description": "metronomic use: capecitabine 500mg/tid", 
                "intervention_name": "Capecitabine", 
                "intervention_type": "Drug", 
                "other_name": "Xeloda"
            }, 
            {
                "arm_group_label": "Metronomic Capecitabine  and AI", 
                "description": "Anastrozole 1mg/day p.o,Exemestane 25mg/day,Letrozole 2.5mg/day p.o.", 
                "intervention_name": "aromatase Inhibitors (AIs)", 
                "intervention_type": "Drug", 
                "other_name": "Exmestane or Letrozol or Anastrozol"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Hormones", 
                "Aromatase Inhibitors", 
                "Capecitabine", 
                "Fluorouracil"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "breast cancer", 
            "metronomic chemotherapy", 
            "aromatase inhibitors"
        ], 
        "lastchanged_date": "August 14, 2013", 
        "location": {
            "contact": {
                "email": "liugy123@yahoo.com", 
                "last_name": "Guang-Yu Liu, MD", 
                "phone": "86-021-64175590", 
                "phone_ext": "8808"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200032"
                }, 
                "name": "FUSCC"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Capecitabine Metronomic Chemotherapy Combined With Aromatase Inhibitors in Postmenopausal Hormone-receptor-positive Breast Cancer", 
        "overall_contact": {
            "email": "liugy123@yahoo.com", 
            "last_name": "Guang-Yu Liu, MD", 
            "phone": "86-021-64175590", 
            "phone_ext": "8808"
        }, 
        "overall_contact_backup": {
            "email": "doctorljw@yahoo.com", 
            "last_name": "Jian-wei Li, MD", 
            "phone": "86-021-64175590", 
            "phone_ext": "8808"
        }, 
        "overall_official": {
            "affiliation": "Fudan University", 
            "last_name": "Guang-yu Liu, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "adverse events (Hand-foot syndrome,Gynecological events, blood lipids, thrombosis, cardiovascular diseases,and etc.)", 
            "measure": "adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "average 10 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01924078"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Guangyu Liu", 
            "investigator_title": "Vice Director of Department of Surgical Oncology,Cancer Hospital & Institute", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Progression-free survival (PFS)", 
                "measure": "PFS", 
                "safety_issue": "No", 
                "time_frame": "average 10 months"
            }, 
            {
                "description": "time to treatment failure\uff08TTF)", 
                "measure": "TTF", 
                "safety_issue": "No", 
                "time_frame": "average 10 months"
            }
        ], 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fudan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2010", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}